- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 19.08. | BiomX Inc: BiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis | 464 | GlobeNewswire (Europe) | U.S. FDA has placed a clinical hold on the Phase 2b study as it reviews data submitted by BiomX on third-party nebulizer used to deliver BX004; no concerns were raised in the clinical hold notification... ► Artikel lesen | |
| 13.08. | BiomX outlines BX004 Phase IIb results expected in Q1 2026 as BX211 advances toward registrational study | 1 | Seeking Alpha | ||
| 13.08. | BiomX Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| BIOMX Aktie jetzt für 0€ handeln | |||||
| 13.08. | BiomX GAAP EPS of -$0.19 | 3 | Seeking Alpha | ||
| 13.08. | BiomX Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.08. | BiomX Inc: BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates | 302 | GlobeNewswire (Europe) | Positive Phase 2 results for BX211 demonstrated >40% wound size reduction vs. placebo in diabetic foot osteomyelitis patients; Planning underway for potential registrational study Nature Communications... ► Artikel lesen | |
| 12.08. | What to Expect from BiomX's Earnings | 1 | Benzinga.com | ||
| 06.08. | BiomX Inc: BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025 | 1 | GlobeNewswire (USA) | ||
| 30.07. | BiomX Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 15.07. | BiomX stock holds Buy rating at H.C. Wainwright as Phase 2b trial begins | 3 | Investing.com | ||
| 15.07. | BiomX stock maintains Buy rating at H.C. Wainwright with $15 price target | 1 | Investing.com | ||
| 14.07. | BiomX stock soars after initiating Phase 2b trial for cystic fibrosis therapy | 2 | Investing.com | ||
| 14.07. | BiomX-Aktie schießt nach Start von Phase-2b-Studie für Mukoviszidose-Therapie in die Höhe | 4 | Investing.com Deutsch | ||
| 14.07. | BiomX startet Phase-2b-Studie mit Phagentherapie gegen Infektionen bei Mukoviszidose | 1 | Investing.com Deutsch | ||
| 14.07. | BiomX begins phase 2b trial for phage therapy targeting CF infections | 1 | Investing.com | ||
| 14.07. | BiomX Inc: BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis | 194 | GlobeNewswire (Europe) | First patient dosing in Company's Phase 2b trial marks pivotal milestone in phage therapy development program targeting antibiotic-resistant lung infections in Cystic Fibrosis patients; topline results... ► Artikel lesen | |
| 08.07. | BiomX Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 09.06. | BiomX Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 16.05. | H.C. Wainwright cuts BiomX stock target to $15, maintains Buy | 6 | Investing.com | ||
| 15.05. | BiomX Inc. - 10-Q, Quarterly Report | 1 | SEC Filings |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 96,05 | +0,05 % | BioNTech: Chancen in Onkologie, Sorgen im Kurs | Die Aktie von BioNTech SE notiert aktuell bei 94,73 EUR. Nach dem beispiellosen Erfolg mit dem COVID-19-Impfstoff steht das Mainzer Biotech-Unternehmen vor der Herausforderung, seine Pipeline in Onkologie... ► Artikel lesen | |
| AMGEN | 242,45 | +0,17 % | Amgen investiert über 600 Millionen Dollar in Innovationszentrum | Der US-Biotechkonzern Amgen will an seinem Hauptsitz im kalifornischen Thousand Oaks ein neues Zentrum für Wissenschaft und Innovation errichten. Für das Projekt sind Investitionen von mehr als 600... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 2,340 | -1,68 % | Inovio: Fortschritte bei DNA-Medizin und Zulassungsantrag für INO-3107 in Aussicht | ||
| CARDIOL THERAPEUTICS | 0,911 | -1,62 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
12.08.2025 / 13:31 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,061 | -1,78 % | PACB Partners With EpiCypher to Advance Epigenomics Using Fiber-Seq | ||
| REDHILL BIOPHARMA | 1,450 | +13,28 % | RedHill Biopharma Ltd.: RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights | Extensive strategic, financial and operational overhaul has reshaped and refocused our business; Strong progress on multiple fronts
Commercial and R&D Highlights:
... ► Artikel lesen | |
| FIBROGEN | 12,050 | 0,00 % | FibroGen stock maintains Buy rating at H.C. Wainwright after China sale | ||
| LEXAGENE | - | - | LexaGene Holdings Inc. - REVOKED, Commission order revoking Exchange Act registration [Section 12(j)] | ||
| ALLAKOS | 0,255 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 15.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 15.05.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 15.05.2025.ISIN NameCA05259R1073 AUSTRALIS... ► Artikel lesen | |
| VERRICA PHARMACEUTICALS | 4,240 | -2,75 % | XFRA 1NE0: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| VAXCYTE | 27,200 | -3,55 % | Vaxcyte, Inc.: Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose | VAX-31 Optimized Dose, with Majority of Serotypes Dosed at 4.4mcg and Balance at 3.3mcg, is Designed to Elicit Even Stronger Immune Responses in Infant Population to Protect Against Invasive Pneumococcal... ► Artikel lesen | |
| HOOKIPA PHARMA | 0,870 | +3,55 % | HOOKIPA Pharma Inc.: HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock | NEW YORK and VIENNA, July 18, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, "HOOKIPA"), a clinical-stage biopharmaceutical company developing next-generation immunotherapeutics for the... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 3,355 | +2,91 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | DALLAS, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based... ► Artikel lesen | |
| QIAGEN | 40,390 | +0,44 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Dies schrieb Analyst Tycho Peterson in seinem am Freitag... ► Artikel lesen | |
| NUVALENT | 80,89 | +1,53 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen |
BIOMX INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,005 (-0,95 %) liegt der Kurs bei 0,513 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOMX INC finden Sie auf Wallstreet Online.